ACTON, Mass.--(BUSINESS WIRE)--Sept. 13, 2006--Neuroptix Corporation, a Massachusetts-based Alzheimer's diagnostics company, today announced that recent tests of its Optiscan(TM) diagnostic platform on mice demonstrated that the optical scanning system was able to detect amyloid protein aggregates in the lens of the eye prior to toxic plaque build-up in the brain.
